Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
$9.21
+1.2%
$9.10
$0.06
$14.93
$6.96M0.98562,718 shs4,504 shs
SPDR S&P Dividend ETF stock logo
SDY
SPDR S&P Dividend ETF
$138.62
+0.2%
$134.87
$119.83
$144.45
$20.35B0.86256,626 shs218,581 shs
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
+1.21%+1.55%+0.77%+0.77%-74.42%
SPDR S&P Dividend ETF stock logo
SDY
SPDR S&P Dividend ETF
+0.24%+0.07%+2.26%+9.82%+9.82%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
1.4864 of 5 stars
3.50.00.00.02.50.00.0
SPDR S&P Dividend ETF stock logo
SDY
SPDR S&P Dividend ETF
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
3.00
Buy$275.002,885.88% Upside
SPDR S&P Dividend ETF stock logo
SDY
SPDR S&P Dividend ETF
2.44
Hold$138.62N/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
$146K48.19N/AN/A$0.20 per share46.05
SPDR S&P Dividend ETF stock logo
SDY
SPDR S&P Dividend ETF
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
-$28.96M-$24.00N/AN/AN/A-12,594.21%-421.73%-147.54%N/A
SPDR S&P Dividend ETF stock logo
SDY
SPDR S&P Dividend ETF
N/AN/A19.85N/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
N/AN/AN/AN/AN/A
SPDR S&P Dividend ETF stock logo
SDY
SPDR S&P Dividend ETF
$3.562.57%N/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
0.05
0.75
0.75
SPDR S&P Dividend ETF stock logo
SDY
SPDR S&P Dividend ETF
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
12.02%
SPDR S&P Dividend ETF stock logo
SDY
SPDR S&P Dividend ETF
43.42%

Insider Ownership

CompanyInsider Ownership
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
0.02%
SPDR S&P Dividend ETF stock logo
SDY
SPDR S&P Dividend ETF
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
20764,00068.74 millionNot Optionable
SPDR S&P Dividend ETF stock logo
SDY
SPDR S&P Dividend ETF
N/A146.80 millionN/ANot Optionable

Recent News About These Companies

Money dispenser for dividends
5 High-Yielding ETFs to Buy and Hold Forever (SDY)
...
SDY's Holdings Imply 10% Gain Potential
SDY SPDR® S&P Dividend ETF
VIDEO: ETF of the Week: SDY
5 Good ETFs to Invest in and Forget
ETF of the Week: SPDR S&P Dividend ETF (SDY)
Turning to Dividend ETFs for Stability
SDY: Aristocrats Can Beat In Uncertainty
Final Trade: SDY, TJX, ZM, GIS

New MarketBeat Followers Over Time

AIM ImmunoTech stock logo

AIM ImmunoTech NYSE:AIM

$9.21 +0.11 (+1.21%)
As of 07/9/2025 02:27 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

SPDR S&P Dividend ETF stock logo

SPDR S&P Dividend ETF NYSEARCA:SDY

$138.62 +0.33 (+0.24%)
Closing price 07/9/2025 04:10 PM Eastern
Extended Trading
$138.45 -0.17 (-0.12%)
As of 05:06 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

The SPDR S&P Dividend ETF seeks to closely match the returns and characteristics of the S&P High Yield Dividend Aristocrats Index (the Index). The Index is designed to measure the performance of the 60 highest dividend yielding S&P Composite 1500 Index constituents that have followed a managed-dividends policy of consistently increasing dividends every year for at least 25 consecutive years. The Fund generally invests substantially all, but at least 80%, of its total assets in the securities comprising the Index. In addition, the Fund may invest in equity securities that are not included in the Index, cash and cash equivalents or money market instruments, such as repurchase agreements and money market funds (including money market funds advised by the Adviser). SSgA Funds Management, Inc. is the investment adviser to the Fund.